Pinealon is a synthetic tripeptide: glutamic acid, aspartic acid, and arginine, written as Glu-Asp-Arg or EDR. Its CAS number is 175175-23-2 and its formula is C15H26N6O8. It comes out of the work of Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, the same group behind a series of "short peptide bioregulators." The EDR sequence was originally isolated from Cortexin, a polypeptide preparation derived from animal brain tissue and used clinically in Russia.
That origin matters for one reason: nearly all of the published research on Pinealon comes from this one research group and is preclinical. It is sold as a research chemical, not approved as a drug in the US, EU, or Canada, and nothing here is medical, dosing, or efficacy advice.
What the proposed mechanism is
The Khavinson group's central hypothesis is that very short peptides like EDR can enter cells, reach the nucleus, and bind directly to DNA or chromatin-associated proteins, nudging the transcription of specific genes. In a 2021 review and modeling paper in Molecules, the authors describe EDR binding to particular DNA sequences (they name CCTGCC and CCAGC) and to histone proteins, and link this to changes in genes tied to antioxidant defense (SOD2, GPX1), inflammation (PPARA, PPARG), and serotonin synthesis (Khavinson et al., 2021, *Molecules*). This is a proposed mechanism backed by molecular modeling and cell work, not a settled, independently replicated pathway.
What was actually tested
The documented studies are in cell cultures and rodents.
- In a 2011 paper in Rejuvenation Research, Pinealon reduced reactive oxygen species and necrotic cell death in cultured cerebellar granule cells, neutrophils, and PC12 cells placed under oxidative stress, with the effect tracking dose and involving delayed ERK 1/2 signaling (Khavinson et al., 2011).
- In a 2012 study, giving Pinealon to pregnant rats loaded with methionine (a model of prenatal hyperhomocysteinemia) improved the offspring's spatial learning and made their cerebellar neurons more resistant to oxidative stress (Arutjunyan et al., 2012, PubMed).
- The 2021 Molecules work also reports effects in transgenic Alzheimer's-model mice, including reduced neuronal apoptosis and preserved dendritic spines.
Human evidence is thin. References to improved cognition in elderly patients trace back to small Russian clinical reports, not large randomized trials, and there are no Phase II/III trials registered in Western frameworks.
Regulatory and quality notes
Pinealon has no approved drug status in major Western jurisdictions; it circulates as a research-use-only material. Because it isn't a pharmaceutical, no regulator is checking what's in a given vial. For a three-residue peptide sold by many vendors, the buyer-relevant questions are identity and purity: does the product match Glu-Asp-Arg, and how much of it is the intended peptide versus salts, water, or synthesis byproducts. A current third-party certificate of analysis (ideally mass spec for identity plus HPLC for purity), tied to the specific batch, is the only document that speaks to that. peptideone aggregates vendor COAs and independent rater signals so those claims can be compared rather than taken on faith.
WADA does not list Pinealon by name, but athletes should treat any unapproved peptide cautiously, since broad catch-all categories can apply.